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“FORK AND BRACKET” SYNDROME EXPANDS
THE SPECTRUM OF SBF1-RELATED SENSORY
MOTOR POLYNEUROPATHIES
Charcot-Marie-Tooth neuropathy type 4 (CMT4)
comprises a large group of genetically heteroge-
neous progressive sensory motor neuropathies char-
acterized by autosomal recessive inheritance.
Among these, CMT4B includes 3 forms related to
genes of the myotubularin family, namely
CMT4B1 (MTMR2), CMT4B2 (MTMR13/
SBF2), and CMT4B3 (MTMR5/SBF1).
Only 2 CMT4B3 families have been reported to
date. In the original Korean family, 3 siblings showed
a homogeneous phenotype of pure sensory motor
demyelinating neuropathy with focally folded myelin
sheaths, closely resembling CMT4B1 and CMT4B2.
All patients had onset of distal atrophy and weakness
in upper and lower limbs, decreased vibration and
position sense, areflexia, and pes planus in the first
decade, with a slow progression to loss of ambulation
in the fifth decade of life. None had cognitive impair-
ment, dysmorphic features, or obvious extraneuro-
logic syndromic manifestations.1
In the second SBF1-mutated family, from Saudi
Arabia, the 3 affected siblings presented a more
complex syndromic phenotype. Sensory motor pol-
yneuropathy was associated with progressive micro-
cephaly, intellectual disability, syndactyly, and
multiple cranial nerve involvement, which resulted
in ophthalmoparesis, absence of pupil reactivity to
light, mild facial weakness, swallowing difficulties,
and dysarthria. There was distal muscle wasting and
weakness but no pes cavus. Brain MRI showed
unspecific diffuse brain atrophy.2
We further expand the phenotypic spectrum of
SBF1-associated CMT to include “fork and
bracket” syndrome, a peculiar condition that we
previously described in a Syrian family.3 The 2
affected siblings from this family were recently re-
assessed, and whole-exome sequencing was performed
in the proband. Only the SBF1 homozygous p.L335P
mutation survived the filtering pipeline (e-Methods and
figure e-1 at Neurology.org/ng). The 2 siblings shared
relevant features with the Saudi Arabian family, includ-
ing early-onset progressive microcephaly, multiple
cranial nerve neuropathies, and moderate to severe
intellectual disability. Moreover, the sister
recently developed a severe oromandibular dysto-
nia that impaired mouth closure, making it
difficult to eat and speak. In contrast to
CMT4B1, CMT4B2, and the pure neuropathic
form of CMT4B3, which are all characterized by
demyelinating neuropathy with focally folded
myelin sheaths, both families presented a predom-
inantly axonal sensory motor neuropathy with
evidence of denervation, markedly reduced
amplitude of action potentials, and relatively pre-
served nerve conduction velocities (table e-1).
However, there were also clinical differences, as
proprioception, touch, and temperature sensa-
tions were largely spared in the 2 Syrian siblings
and they both had joint laxity and thumb sign but
no syndactyly. Furthermore, their brain MRI
showed peculiar anomalies at the pontine and
mesencephalic level described as the “fork and
bracket sign” (figure e-2),3 presumably related to
the presence of degenerated fiber bundles of ocu-
lomotor and facial nerves, which were not reported
in the Saudi Arabian family (see table e-2 for a
detailed phenotypic comparison among the 3
families).
There seem to be relevant genotype–phenotype
correlations in CMT4B3, as the Korean patients with
pure demyelinating neuropathy were compound het-
erozygous for 2 missense variants, both predicted as
benign or tolerated by most prediction software,
suggesting a mild impact on the protein. On the con-
trary, the 2 families with severe syndromic presenta-
tion carried missense mutations that were consistently
predicted to be deleterious for the protein structure or
function (figure 1A).
SBF1 is part of the myotubularin family, a large
and highly conserved group of ubiquitously expressed
phosphatidylinositol 3-phosphatases encompassing
catalytically active (including MTMR2) and inactive
(including SBF1 and SBF2) enzymes that share a core
of protein domains.4 Most MTMR2 mutations are
truncating or missense changes that drastically reduce
phosphatase activity, suggesting loss of function of
the protein as the key mechanism leading to
CMT4B1. Both SBF1 and SBF2 proteins interact
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directly with MTMR2 in the cytosol, markedly
increasing its enzymatic activity5; the impairment of
this interaction, possibly related to protein absence,
subcellular mislocalization, or functional changes of
the interacting C-terminus domains, is a likely mech-
anism to explain the polyneuropathy associated with
mutations in both genes. However, the severe syn-
dromic phenotype shown by 2 SBF1-mutated fami-
lies calls for additional explanations.
Of note, both mutations causative of syndromic
CMT4B3 fall within the DENN domain (figure
1B), shared only by SBF1 and SBF2 among myo-
tubularins.4 This domain was implicated in
membrane trafficking and endosome function5 as
well as in regulation of the proteins’ subcellular
localization, which suggests that it may confer
additional functions to SBF1 and SBF2 besides
interaction with MTMR2.6 However, an SBF2
deletion abolishing the whole D-DENN module
caused nonsyndromic demyelinating neuropathy
in a Turkish family.7 This phenotypic variability
may relate to yet unknown differences between
SBF1 and SBF2 in their function and/or tissue
expression pattern or to a more deleterious impact
of missense mutations on the protein structure
and function.
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Figure 1 Prediction of pathogenicity and protein localization of SBF1 mutations
(A) Predicted pathogenicity of SBF1missense mutations according to 4 distinct software programs (PolyPhen-2, SIFT, Mutation Assessor, and MetaLR). For
each software program, predicted pathogenicity is represented as a spectrum of increasing severity, from white (tolerated/benign variants) to black (del-
eterious variants). SBF1mutations are reported with vertical lines of different colors (blue: Korean family; green: Saudi Arabian family; yellow: Syrian family)
(see e-Methods for more details). (B) Schematic structure of SBF1 protein and site of mutations. Abbreviation of domains is as follows: DENN5 differentially
expressed in neoplastic vs normal cells domain, made by the 3 modules uDENN (U), DENN, and dDENN (D); GRAM 5 glucosyltransferase, Rab-like GTPase
activators and myotubularins; RID 5 Rac-induced recruitment domain; phosphatase 5 inactive catalytic domain of tyrosine and dual-specificity phospha-
tase; CC 5 coiled coil domain; PH 5 pleckstrin homology domain.
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